What is it about?
Malignant mesothelioma (MM) is an aggressive, and current therapeutic options only marginally improve survival. PD-L1 pathway plays a critical role in tumour immune evasion, thus providing a target for antitumor therapy. Determination of PD-L1 expression in Mesothelioma was performed on histological material , but no study has been performed on MM effusions thus far. PD-L1 expression was determined by a commercially available antibody (clone 28-8) in 74 formalin-fixed, paraffin-embedded cell blocks from body effusions obtained at diagnosis from patients with MM.
Featured Image
Why is it important?
Our findings show that the effusion cytology are suitable for immuncytochemical assessment of PD-L1 expression in MM malignant cells and the results are similar to those reported for histological specimens.
Perspectives
I hope this article leads to utilizing of cytological material in best way in order to fast and mild investigation for patients, and avoiding delaying of diagnosis and treatment.
Dr. Mohammed S. I. Mansour
Region Halland
Read the Original
This page is a summary of: Determination of PD-L1 expression in effusions from mesothelioma by immuno-cytochemical staining, Cancer Cytopathology, September 2017, Wiley,
DOI: 10.1002/cncy.21917.
You can read the full text:
Resources
Contributors
The following have contributed to this page
